Weekly Digest – January 2026 Weekly Digest – January 2026 12 January 2026: The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has included SHR-1826 in its list of breakthrough therapies for non-squamous non-small cell lung […]
Weekly Digest – January 2026 Weekly Digest – January 2026 12 January 2026: SK Biopharm wins FDA approval for Phase 1 trial of alpha-emitter cancer therapy SK Biopharm announced that it has received U.S. FDA approval for an investigational new […]
Weekly Digest – January 2026 Weekly Digest – January 2026 13 January 2026: TROPION-Lung17 TROP2 biomarker directed Phase 3 trial of DATROWAY initiated in patients with previously treated advanced non-squamous non-small cell lung cancer The first patient has been dosed […]
Weekly Digest – January 2026 Weekly Digest – January 2026 12 January 2026: Summit Therapeutics announces clinical trial collaboration with GSK to evaluate Ivonescimab in combination with GSK’s B7-H3 antibody drug conjugate (ADC) Summit Therapeutics announced a clinical trial collaboration […]
Weekly Digest – January 2026 Weekly Digest – January 2026 13 January 2026: Mabion S.A. and Celon Pharma S.A. plan to initiate collaboration in the development of ADC products Mabion S.A. and Celon Pharma S.A. announced plans to initiate a […]
Weekly Digest – January 2026 Weekly Digest – January 2026 09 January 2026: MediLink has signed an additional exclusive licensing agreement with Roche MediLink Therapeutics announced that it has entered into an additional exclusive licensing and collaboration agreement with Roche […]
